Evidence map›Paper›PMID 40229918›Full record

ArticleClinical and translational allergy2025

Factors that influence user adherence of the Mask-air® application.

Anna Szylling, Boleslaw Samoliński, Filip Raciborski, Konrad Furmańczyk, Mariola Chrzanowska, Oksana Wojas, Edyta Krzych-Fałta, Emilia Gawińska-Drużba, Krzysztof Samoliński, Jean Bousquet and 1 more

Abstract read
In one paragraph

Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anna SzyllingDepartment of Allergy and Clinical Immunology, University Clinical Center of the Medical University of Warsaw Central Clinical Hospital, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0009-0003-6983-9621
Boleslaw SamolińskiDepartment of Allergy and Clinical Immunology, University Clinical Center of the Medical University of Warsaw Central Clinical Hospital, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0002-4043-7747
Filip RaciborskiDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0003-0562-0260
Konrad FurmańczykDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0002-7683-4787
Mariola ChrzanowskaDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0002-8743-7437
Oksana WojasDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0003-1653-9388
Edyta Krzych-FałtaDepartment of Basic of Nursing, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0002-9857-7136
Emilia Gawińska-DrużbaDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.
Krzysztof SamolińskiDepartment of Emergency Medical Services, Medical University of Warsaw, Warszawa, Poland.
Jean BousquetInstitute of Allergology, Charite Universitatsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4061-4766
Piotr Samel-KowalikDepartment of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.ORCID https://orcid.org/0000-0002-9047-0414

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMonitoring adherence in chronic diseases remains a significant challenge. Allergic rhinitis (AR), one of the most common chronic conditions, serves as an excellent model for studying determinants of app use in monitoring adherence and health assessment during treatment. The Mask-air® app supports clinical decision-making by involving patients in symptom observation and promoting adherence to therapy. This study aimed to identify the defining characteristics of Mask-air® users, describe their disease phenotype and satisfaction with the app, and explore reasons for discontinuation. MATERIALS AND

methodsAdult patients 20-44 years old suffering from AR (n = 198) receiving care at an allergy outpatient clinic were invited to participate in a trial using the Mask-air® app. Investigators collected data on symptoms, administered treatments, and clinical evaluation results through questionnaires. At a follow-up visit (n = 163), these were compared, and patients were questioned about their satisfaction with the app. Patients presented their app records, and those who declined or stopped using the app were asked to provide reasons in a questionnaire.

resultsNo distinguishing characteristics of Mask-air® users (n = 131) were identified compared with those who declined the app (n = 67). App readiness was analyzed according to age, socioeconomic status, disease severity, comorbidities, and therapeutic modality. Respondents were categorized into: those who did not install the app (17.7%), those who installed but did not use it (16.2%), and those who installed and evaluated it (66.2%), with 15.6% failing to produce symptom monitoring records. Overall, satisfaction ratings were high though patients were critical of the app's therapeutic aspect.

conclusionsThe study found no specific features distinguishing Mask-air® users, suggesting that it can be recommended to all patients regardless of gender, socioeconomic or educational status, or disease phenotype. However, with a dropout rate of nearly 50%, it is essential for clinicians to emphasize the app's benefits to improve adherence and engagement.

Indexed as

adherenceallergic rhinitisCDSSMask‐air®

Identifiers

PMID40229918
PMCPMC11996621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.